LEAP-001 trial: what clinicians have said so far
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
- NCT03884101 ↗
- Completed
- Merck Sharp & Dohme LLC
- Deep size, estimated: 301+ verified statements once built
Discussed at: ESMO Congress 2026
We haven't built an HCP commentary report on LEAP-001 (lenvatinib plus pembrolizumab in first-line advanced or recurrent endometrial cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 40 most recent indexed sources
Automated from the 40 newest of 66 indexed sources (Apr 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether patients with prior (neo)adjuvant platinum gain more from lenvatinib-pembrolizumab than from carboplatin-paclitaxel
- Whether carboplatin-paclitaxel alone remains a relevant control arm now that chemotherapy plus immunotherapy is standard
- Whether the dMMR subgroup supports dropping chemotherapy from first-line immunotherapy-based treatment
Indexed commentary on LEAP-001 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 28 podcast episodes, typically up to 123 once built | |
| 27 YouTube videos, typically up to 119 once built | |
| 11 posts on X, typically up to 48 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Endometrial Neoplasms
- Interventions
- Lenvatinib; Pembrolizumab; Paclitaxel; Carboplatin
- Arms
- Lenvatinib + Pembrolizumab · Experimental
- Paclitaxel + Carboplatin · Active comparator
- Enrollment
- 842
- Primary outcomes
- Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants
- PFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants
- Overall Survival (OS) in pMMR Participants
- OS in All Randomized Participants
- Sponsor
- Merck Sharp & Dohme LLC with Eisai Inc.
- Start
- Apr 11, 2019
- Primary completion
- Oct 2, 2023
- Results posted
- Yes
- Registry record
- NCT03884101 · updated Feb 2, 2026
Publications
linked from the registry- Marth C, Moore RG, Bidzinski M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2025 Mar 20;43(9):1083-1100. doi: 10.1200/JCO-24-01326. Epub 2024 Nov 26. PubMed 39591551
- Marth C, Lorusso D, Bidzinski M, Scollo P, Vardar MA, Oaknin A, Kaen DL, Nogueira-Rodrigues A, Miller DS, Hasegawa K, MacKay H, Moore RG, Santin AD, Yunokawa M, Romero I, Pignata S, Baron-Hay S, Kim YM, Amit A, Ghamande S, Danska-Bidzinska A, Tarnawski R, Wang PH, Yu Z, Slomovitz BM, Okpara CE, McKenzie J, Meng R, Orlowski R, Makker V. Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes. Int J Gynecol Cancer. 2026 Jul;36(7):104693. doi: 10.1016/j.ijgc.2026.104693. Epub 2026 Apr 12. PubMed 42167105
- Marth C, Moore RG, Bidzinski M, Salutari V, Altundag O, Rubio MJ, Levy T, Stillie A, Vulsteke C, Witteler R, Ariyoshi K, Wu X, Frentzas S, Mattar A, Slomovitz BM, Lheureux S, Chen X, Hasegawa K, Magallanes M, Choi CH, Shalkova M, Kaen DL, Cadoo K, Yao L, McKenzie J, Okpara CE, Meng R, Orlowski R, Gilbert L, Makker V. First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial. Int J Gynecol Cancer. 2026 Jan;36(1):102795. doi: 10.1016/j.ijgc.2025.102795. Epub 2025 Nov 11. PubMed 41494216
- Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19. PubMed 34799418